Since the Cardiac Arrhythmia Suppression Trial , which showed some dangerous effects of class I sodium channel blocking anti-arrhythmic drugs on patients with ischemic heart disease, class III drugs, especially new D-sota-lol-like drugs, have become a centre of interest for pharmacologists and cardiologists. We have been examining class III drugs for several years using canine arrhythmia models to characterize individual new drugs . New synthetic class III antiarrhythmic agents of Vaughan Williams’ classification inhibit cardiac potassium channels, but have no effect on the cardiac calcium and sodium channels. As a result of this effect, they prolong action potential duration as well as effective refractory period (ERP).We used canine automaticity ventricular arrhythmias following two-stage coronary ligation, digitalis and adrenaline administration , and canine reentry type arrhythmias, ie, the coronary ligation and reperfusion-induced ventricular arrhythmia model and programmed electrical stimulation (PES) -induced arrhythmia in dogs with ‘old’ (seven to 10 days) myocardial infarction. The drugs used were E-4031 , MS-551 , D-sotalol , sematilide , dofetilide and amiodarone , which has already been reported, and KCB 328. KCB 328 is a new D-sotalol derivative currently under preclinical evaluation (Figure 1). It’s your turn to find generic sildenafil online cialis professional to see how advantageous your shopping can be.
Figure 1 Chemical structure of KCB 328